CPHI Stock Overview
Develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
China Pharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$0.60 |
| 52 Week Low | US$0.13 |
| Beta | 0.61 |
| 1 Month Change | 12.77% |
| 3 Month Change | -8.34% |
| 1 Year Change | -57.30% |
| 3 Year Change | -98.99% |
| 5 Year Change | -98.50% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.5% | 0.4% | -2.1% |
| 1Y | -57.3% | 2.2% | 21.3% |
Return vs Industry: CPHI underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: CPHI underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| CPHI volatility | |
|---|---|
| CPHI Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CPHI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CPHI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 231 | Zhilin Li | www.chinapharmaholdings.com |
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
China Pharma Holdings, Inc. Fundamentals Summary
| CPHI fundamental statistics | |
|---|---|
| Market cap | US$4.06m |
| Earnings (TTM) | -US$4.74m |
| Revenue (TTM) | US$5.54m |
0.8x
P/S Ratio-0.9x
P/E RatioIs CPHI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHI income statement (TTM) | |
|---|---|
| Revenue | US$5.54m |
| Cost of Revenue | US$7.45m |
| Gross Profit | -US$1.90m |
| Other Expenses | US$2.84m |
| Earnings | -US$4.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | -34.34% |
| Net Profit Margin | -85.56% |
| Debt/Equity Ratio | 60.5% |
How did CPHI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 09:27 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Pharma Holdings, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin DeGeeter | Ladenburg Thalmann & Company |
| Reni Benjamin | Rodman & Renshaw, LLC |
| Scott Henry | Roth MKM |